Asthma Protocol
Primary Stack
Core supplements with strongest evidenceNatural bronchodilator that relaxes airway smooth muscle and may reduce airway hyperreactivity
Modulates immune function, reduces airway inflammation, and may decrease exacerbation frequency
Supporting Stack
Additional supplements for enhanced resultsModulates gut-lung immune axis; may reduce allergic inflammation and improve immune tolerance
Supporting Studies (1)
EPA and DHA reduce inflammatory mediators (leukotrienes) involved in airway inflammation
Supporting Studies (1)
Thymoquinone has anti-inflammatory and bronchodilator effects; traditional remedy for respiratory conditions
Supporting Studies (1)
Flavonoid that stabilizes mast cells, inhibits histamine release, and has anti-inflammatory effects
Supporting Studies (1)
Contains crocin and safranal which may reduce airway inflammation and improve lung function
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Asthma is a chronic inflammatory disease of the airways characterized by wheezing, shortness of breath, chest tightness, and coughing. It involves airway inflammation, hyperreactivity (overly sensitive airways), and reversible obstruction. While controller medications (inhaled corticosteroids, bronchodilators) are the foundation of treatment, certain supplements may provide additional support for airway health and reduce inflammation.
IMPORTANT: Supplements do not replace asthma medications. Never stop or reduce prescribed medications without consulting your doctor. Have a rescue inhaler available for acute symptoms.
Expected timeline: Magnesium: 1-2 weeks. Vitamin D: 2-3 months (based on correcting deficiency). Probiotics: 4-8 weeks. Omega-3: 6-12 weeks for anti-inflammatory effects. Black seed/saffron: 4-8 weeks.
Clinical Perspective
Asthma involves chronic airway inflammation (eosinophilic, neutrophilic, or mixed), airway hyperresponsiveness, mucus hypersecretion, and airway remodeling. Pathophysiology includes Th2-mediated inflammation (IL-4, IL-5, IL-13), mast cell activation, IgE production, and leukotriene synthesis. This protocol targets inflammation modulation and bronchodilation as adjuncts to standard pharmacotherapy.
CRITICAL: Supplements are adjunctive only. Maintain inhaled corticosteroids and rescue medications per asthma action plan. Monitor peak flow and symptoms closely.
Biomarker targets: Peak expiratory flow (PEF), spirometry (FEV1, FEV1/FVC), FeNO (fractional exhaled nitric oxide), symptom scores (ACT, ACQ), exacerbation frequency, serum 25(OH)D, serum magnesium, IgE levels.
Protocol notes: Allergen avoidance and trigger identification are foundational. Address GERD (can worsen asthma). Weight loss improves asthma control in obesity. Regular physical activity (with proper warm-up) is beneficial despite exercise-induced symptoms. Avoid beta-blockers and NSAIDs if sensitive. Monitor for aspirin-exacerbated respiratory disease (AERD). Consider allergy immunotherapy for allergic triggers. Smoking cessation is critical. Influenza and pneumococcal vaccines recommended. Occupational asthma requires exposure elimination. Severe asthma may benefit from biologics (omalizumab, mepolizumab, dupilumab).